![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SPATA33 |
Gene summary for SPATA33 |
![]() |
Gene information | Species | Human | Gene symbol | SPATA33 | Gene ID | 124045 |
Gene name | spermatogenesis associated 33 | |
Gene Alias | C16orf55 | |
Cytomap | 16q24.3 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q96N06 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
124045 | SPATA33 | P127T-E | Human | Esophagus | ESCC | 1.72e-04 | 9.75e-02 | 0.0826 |
124045 | SPATA33 | P128T-E | Human | Esophagus | ESCC | 1.60e-13 | 4.07e-01 | 0.1241 |
124045 | SPATA33 | P130T-E | Human | Esophagus | ESCC | 2.96e-34 | 6.66e-01 | 0.1676 |
124045 | SPATA33 | C04 | Human | Oral cavity | OSCC | 1.15e-15 | 8.68e-01 | 0.2633 |
124045 | SPATA33 | C21 | Human | Oral cavity | OSCC | 2.12e-30 | 8.17e-01 | 0.2678 |
124045 | SPATA33 | C30 | Human | Oral cavity | OSCC | 2.02e-27 | 1.03e+00 | 0.3055 |
124045 | SPATA33 | C43 | Human | Oral cavity | OSCC | 3.97e-03 | 7.16e-02 | 0.1704 |
124045 | SPATA33 | C46 | Human | Oral cavity | OSCC | 2.91e-05 | 2.34e-01 | 0.1673 |
124045 | SPATA33 | C51 | Human | Oral cavity | OSCC | 2.33e-07 | 5.11e-01 | 0.2674 |
124045 | SPATA33 | C08 | Human | Oral cavity | OSCC | 1.96e-09 | 2.05e-01 | 0.1919 |
124045 | SPATA33 | LN46 | Human | Oral cavity | OSCC | 4.33e-05 | 2.51e-01 | 0.1666 |
124045 | SPATA33 | SYSMH2 | Human | Oral cavity | OSCC | 1.38e-07 | 3.67e-01 | 0.2326 |
124045 | SPATA33 | SYSMH3 | Human | Oral cavity | OSCC | 5.34e-20 | 5.09e-01 | 0.2442 |
124045 | SPATA33 | SYSMH5 | Human | Oral cavity | OSCC | 4.94e-09 | 2.07e-01 | 0.0647 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPATA33 | SNV | Missense_Mutation | rs368742617 | c.281N>T | p.Ala94Val | p.A94V | Q96N06 | protein_coding | deleterious(0.01) | probably_damaging(0.951) | TCGA-AP-A054-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
SPATA33 | insertion | Frame_Shift_Ins | novel | c.385dupA | p.Ser129LysfsTer7 | p.S129Kfs*7 | Q96N06 | protein_coding | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD | ||
SPATA33 | SNV | Missense_Mutation | rs751571842 | c.203N>T | p.Ser68Leu | p.S68L | Q96N06 | protein_coding | tolerated(0.28) | benign(0.009) | TCGA-86-8674-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | vinblastine | PD |
SPATA33 | SNV | Missense_Mutation | novel | c.51N>C | p.Lys17Asn | p.K17N | Q96N06 | protein_coding | deleterious(0.04) | possibly_damaging(0.66) | TCGA-P3-A5Q5-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |